华润双鹤利民药业被罚100万 近日，华润双鹤（600062）利民药业（济南）有限公司与辰欣药业（603367）股份有限公司，分别领走100万元与300万元罚单。它们生产的同一种药品 ——碳酸氢钠注射液——被检出"可见异物""pH值"两项关键指标不达标，直接触犯了《药品管理法》第九十八条第一款的"高压线"。 | mpa.shandong.gov.cn | 山东省药品监督管理局 | | | 简体 繁体 无障碍 智能问答 进入关怀版 ○ 请输入关键字 搜索 | | --- | --- | --- | --- | --- | | | | | | ● 本站信息 ○ 政务服务 | | 首页 机构职能 政务公开 政务服务 | | | 互动交流 | 数据查询 药品 医疗器械 化妆品 | | .. 首页 > 政务公开 > 重点领域 > 行政执法公示 > 事后公示 > 执法结果 | | | | | | 索引号: 11370000MB284723XW/2026-02637 | | | | 公开方式:主动公开 | | 发布机构: | | | | 组配分类: 执法结果 | | 发文日期: 2026-01-08 | | | | 文件编号 ...

格隆汇1月22日丨辰欣药业(603367.SH)在互动平台表示，公司与国内外客户持续建立市场联系，近两年 暂无出口欧盟国家。 ...

Core Viewpoint - The Shandong Provincial Drug Administration has imposed an administrative penalty on Chanshin Pharmaceutical Co., Ltd. for producing and selling sodium bicarbonate injection that does not meet national drug standards, resulting in a total fine of 3,125,018.20 yuan [1] Group 1: Regulatory Actions - Chanshin Pharmaceutical was fined 3,031,700 yuan and had 30,464 bottles of the non-compliant sodium bicarbonate injection confiscated due to violations of the Drug Administration Law [1] - The company was found to have produced a batch of sodium bicarbonate injection that failed to meet the required standards, specifically regarding visible foreign substances, and was included in a list of 28 batches of non-compliant drugs [1] Group 2: Company Overview - Chanshin Pharmaceutical, established in 1970 and listed on the Shanghai Stock Exchange in September 2017, is a large comprehensive pharmaceutical company located in Jining, Shandong Province [3] - The company operates five industrial parks covering nearly 2,000 acres, employs over 3,000 people, including more than 1,000 technical professionals, and has total assets of 7.5 billion yuan [3] - Chanshin Pharmaceutical offers over 400 specifications of various drug forms, including large-volume injections, small-volume injections, and raw materials, with a sales network spanning across China and over 50 countries and regions [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 ■ 附：据股东韩延振提供的《股票质押式回购交易部分解除质押委托书》显示，其此前于2025年9月11日 解除质押股份2,010,000股，占其当时持股总数的7.32%，占当时公司总股本的0.44%。 2、股东及其一致行动人累计质押情况 截至本公告披露日，公司股东韩延振及其一致行动人江苏辰昕同泰企业管理有限公司累计质押公司股份 数量为0股，不存在通过非经营性资金占用、违规担保、关联交易等侵害上市公司利益的情况。本次股 份解除质押后暂无后续质押计划，若公司股东未来进行股份质押，公司将根据其通知，严格按照相关要 求及时履行信息披露义务。 3、报备文件 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示: ● 截止本公告日，辰欣药业股份有限公司（以下简称"公司）股东韩延振持有公司股份21,269,329股，占 公司总股本比例为4.698%。 ● 韩延振本次解除质押股份11,340,000股，占其所持股份总数的53.32%，占公司总股本的2.50%。本次股 份解除质押后，剩余质押 ...

证券代码：603367 证券简称：辰欣药业 公告编号：2026-003 辰欣药业股份有限公司 关于股东股份解除质押的公告 1 | 剩余被质押股份数量 | 0 股 | | --- | --- | | 剩余被质押股份数量占其所持股份比例 | 0 | | 剩余被质押股份数量占公司总股本比例 | 0 | 附：据股东韩延振提供的《股票质押式回购交易部分解除质押委托书》显示，其此前于 2025 年 9 月 11 日解除 质押股份 2,010,000 股，占其当时持股总数的 7.32%，占当时公司总股本的 0.44%。 2、股东及其一致行动人累计质押情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 截止本公告日，辰欣药业股份有限公司（以下简称"公司）股东韩延振持有公 司股份 21,269,329 股，占公司总股本比例为 4.698%。 韩延振本次解除质押股份 11,340,000 股，占其所持股份总数的 53.32%，占公 司总股本的 2.50%。本次股份解除质押后，剩余质押公司股份 0 股。 公司于 2026 年 1 ...

Group 1 - The National Medical Products Administration of China announced on January 6 that 28 batches of non-compliant drugs were identified, including sodium bicarbonate injection produced by Chenshin Pharmaceutical Co., Ltd., which failed due to visible foreign substances [1] - The visible foreign substances refer to insoluble materials that can be observed under specified visual conditions in injectable and ophthalmic solutions, typically with a particle size or length greater than 50 micrometers [2] Group 2 - Chenshin Pharmaceutical Co., Ltd. is a large comprehensive pharmaceutical enterprise engaged in research and development, production, and sales, listed on the Shanghai Stock Exchange main board in September 2017 [3] - The company is recognized as a national technology innovation demonstration enterprise and a national high-tech enterprise, and it serves as the vice president unit of the China Chemical Pharmaceutical Industry Association [3]

Core Viewpoint - The company plans to utilize idle funds for entrusted wealth management and securities investment, with a total amount not exceeding RMB 2.9 billion, to enhance the efficiency of fund usage and generate returns for shareholders [2][3][14]. Investment Overview - Investment Purpose: The company aims to improve the efficiency of idle funds while ensuring normal business operations and daily capital needs [3]. - Total Investment Amount: The total investment amount will not exceed RMB 2.9 billion, with RMB 2.3 billion allocated for entrusted wealth management and RMB 600 million for securities investment [2][3][14]. - Investment Duration: The investment period is set for 12 months from the approval date of the board meeting [4][14]. Investment Details - Source of Funds: The funds will come from the company's idle self-owned capital [4]. - Investment Methods: Entrusted wealth management will focus on bank wealth management products, income certificates, and funds, while securities investment will include government bonds, bond repurchase agreements, ETFs, and stocks [4][3]. - Approval Process: The investment plan has been approved by the company's board of directors and does not require shareholder meeting approval [6][14]. Impact on the Company - The use of idle funds for wealth management and securities investment will not affect the company's normal cash flow or operations, and it aims to enhance fund returns and protect shareholder interests [8][14]. - Accounting Treatment: The company will account for the entrusted wealth management and securities investment in accordance with relevant accounting standards, reflecting them in the balance sheet and income statement [8].

Focus 1: Yingfang Micro - The company is planning a major asset restructuring by acquiring controlling stakes in Shanghai Xiaokeli Information Technology Co., Ltd., FIRST TECHNOLOGY CHINA LIMITED, and Shiqing Intelligent Technology (Shanghai) Co., Ltd. through a combination of share issuance and cash payment [1] - The transaction is expected to constitute a significant asset restructuring but will not involve related transactions or restructuring listings. The company's stock will be suspended from trading starting January 6, 2026 [1] Focus 2: Nanxing Co. and Yinglian Co. - Nanxing Co. expects to achieve a net profit of 90 million to 120 million yuan for 2025, recovering from a loss of 175 million yuan in the previous year. The significant profit increase is attributed to reduced goodwill impairment in 2024 [2] - Yinglian Co. anticipates a net profit of 32 million to 42 million yuan for 2025, compared to a loss of approximately 39.67 million yuan in the previous year, driven by growth in the fast-moving consumer goods metal packaging sector [2] Focus 3: Victory Energy - The company has completed its stock trading suspension review and will resume trading on January 6, 2026. No undisclosed significant information affecting stock prices was found during the review [3] Performance Highlights - Whirlpool expects a net profit of approximately 505 million yuan for 2025, a 150% increase from the previous year, due to ongoing transformation and efficiency improvements [4] - Taotao Automotive forecasts a net profit of 800 million to 850 million yuan for 2025, representing an 85.5% to 97.1% increase year-on-year, driven by enhanced operational efficiency and market demand [4] - China National Materials Technology anticipates a net profit of 1.55 billion to 1.95 billion yuan for 2025, a growth of 73.79% to 118.64% compared to the previous year, supported by improved product pricing and sales [4] Investment and Restructuring - Weigao Blood Products plans to issue shares to acquire 100% of Weigao Group Medical Polymer Co., Ltd. for 8.511 billion yuan, significantly enhancing the company's asset scale and profitability [6] - Haopeng Technology is set to raise up to 800 million yuan through a private placement to fund energy storage battery projects [6] Control Changes - Hengshi Technology's control has changed following agreements with New Base Information Technology Group, with the new controlling entity holding 9.55% of the total shares [7] Major Projects - Fulian Precision plans to invest 6 billion yuan in a project to produce 500,000 tons of high-end lithium iron phosphate for energy storage [10] - Penghui Energy's board approved plans to issue H-shares and list on the Hong Kong Stock Exchange [11] Other Announcements - The company intends to repurchase A-shares for employee stock ownership plans, with a total budget of 50 million to 100 million yuan [12] - The company reported a 14.75% year-on-year decline in pig sales, with a revenue drop of 36.06% due to market fluctuations [12]

最新公告列表 近日，辰欣药业发布公告称，公司及控股子公司拟使用不超过29亿元的闲置自有资金进行委托理财及证 券投资，其中委托理财额度不超过23亿元，证券投资额度不超过6亿元，使用期限为董事会审议通过之 日起12个月，资金可滚动使用。投资范围包括银行理财产品、收益凭证、基金、国债、债券、ETF、股 票等。该事项已由公司第五届董事会第十一次会议审议通过，无需提交股东会审议。公司表示将加强风 险控制，防范市场、流动性等风险，并按规定披露相关进展。 截至2026年1月5日收盘，辰欣药业（603367）报收于18.21元，较前一交易日上涨5.14%，最新总市值为 82.45亿元。该股当日开盘17.42元，最高18.25元，最低17.42元，成交额达3.67亿元，换手率为4.52%。 《第五届董事会第十一次会议决议【签字盖章】》 《辰欣药业股份有限公司第五届董事会第十一次会议决议公告》 《辰欣药业股份有限公司关于公司及控股子公司使用闲置自有资金进行委托理财及证券投资的公 告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - Chenxin Pharmaceutical (603367) announced plans to utilize idle funds for entrusted wealth management and securities investment, with a total amount not exceeding 2.9 billion yuan, aiming to enhance the efficiency of fund usage and generate higher returns for shareholders [1] Group 1: Investment Plans - The company and its subsidiaries plan to use idle self-owned funds for entrusted wealth management and securities investment, with a total limit of 2.9 billion yuan, including up to 2.3 billion yuan for entrusted wealth management and up to 600 million yuan for securities investment [1] - The investment aims to improve the efficiency of idle funds while ensuring that the company's main business operations and daily capital needs are not affected [1] Group 2: Investment Types - Entrusted wealth management will primarily involve bank wealth management products, income certificates, and funds from financial institutions [1] - Securities investment will focus on government bonds or reverse repos, bonds, ETFs, stocks, and other investments permitted by laws and regulations [1]